Incremental Selective Pressure for Modeling Acquired Resistance

You are reading version 1 of this direction, frozen 2026-10-04. The latest version is version 2.

Version 1 of 230 papers30 conceptsfrozen 2026-10-04

In clinical oncology and microbiology, the greatest challenge is not the initial tumor or infection, but the one that returns after treatment. To understand how cells survive lethal doses of drugs, researchers use a technique called incremental selective pressure. By exposing cell populations to gradually increasing concentrations of a therapeutic agent over months, scientists can "evolve" resistant lineages in the lab, providing a high-resolution map of the molecular adaptations that drive treatment failure.

The Evolutionary Laboratory

The core intuition behind this research direction is that resistance is rarely a single "on/off" switch. Instead, it is a dynamic, multi-step adaptation. To capture this, researchers like Hua Shen and Bozhena Jhas subject sensitive parental cell lines to chronic, escalating doses of inhibitors.

This iterative selection process mimics the clinical reality where sub-lethal drug concentrations in a patient’s body allow the hardiest cells to survive and diversify. As Bozhena Jhas demonstrated in Metabolic Adaptation to Chronic Inhibition of Mitochondrial Protein Synthesis in Acute Myeloid Leukemia Cells, this longitudinal pressure allows cells to develop stable, resistant phenotypes—such as flipping a metabolic switch to glycolysis—that can be systematically compared to their original sensitive state.

Molecular Rewiring and Signaling Axes

Once a resistant sub-line is established, researchers look for the "molecular scaffolding" that supports survival. A recurring theme across these studies is the identification of specific signaling axes—often involving non-coding RNAs or transcription factors—that become upregulated to bypass the drug's effect.

  • Transcription Factors: Youxiang Hou and Bowen Yuan identified the FOXM1–ABCC5 axis as a pump mechanism that nasopharyngeal carcinoma cells use to eject chemotherapy drugs.
  • RNA Regulation: Circular RNAs and microRNAs act as fine-tuners of resistance. For instance, Jun Zhu found that the circ_0061140/miR-136/CBX2 axis drives resistance in ovarian cancer, while Shujun Li showed that targeting miR-221/222 can restore cisplatin sensitivity in breast cancer.

These axes represent the cell's "plan B." When the primary pathway is blocked by a drug, the cell overexpresses these secondary drivers to maintain growth and survival.

Phenotypic Plasticity and Quiescence

Resistance isn't always about new mutations; often, it is about phenotypic plasticity—the ability of a cell to change its state without changing its DNA. Lingyu Zhang highlights this in Activation of NF-κB/ALDH1A1 Signaling Promotes Non-Mutational Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer, where cells adopt a tolerant state through signaling rewiring rather than genetic alteration.

In some cases, cells survive by simply "going to sleep." Lingli Gong discovered a triple-positive subgroup of stem cells in glioblastoma that maintains resistance by staying in a quiescent, sleep-like state, effectively hiding from drugs that target actively dividing cells. Similarly, Yingfang Wang showed that E. coli uses biofilm production as a physical shield to survive antimicrobial exposure.

Re-sensitization: Breaking the Resistance

The ultimate goal of modeling resistance is to find ways to reverse it. By identifying the specific protein or metabolic pathway that a resistant cell relies on, researchers can develop combination therapies that "re-sensitize" the tumor.

Zhewen Xiong demonstrated this by targeting PPARγ signaling in liver cancer. By blocking this adaptive program, they were able to "inflame" the tumor microenvironment and make it vulnerable to immunotherapy again. Other researchers have used natural compounds like emodin, as explored by Wei Zhang, to downregulate NF-κB and restore gemcitabine sensitivity.

By using incremental selective pressure to map the evolutionary trajectory of resistance, these studies move beyond describing that a drug failed, and instead explain how the cell escaped—and how we might trap it again.

Papers in this version

History & citationVersion 2 · 2026-10-04

Current · Permanent link

  1. Version 2 (latest) · 2026-10-04 · 39 papers
  2. Version 1 · 2026-10-04 · 30 papers
Cite this direction

Latest version (a living page):

@misc{lacuna_acquired_resistance_induction_12fb9cf6,
  title = {acquired resistance induction},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/acquired-resistance-induction/rdr_12fb9cf6632e456ab8663e08b2bc742b},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-22},
}

This exact version (version 1, frozen text):

@misc{lacuna_incremental_selective_pressure_for_model_12fb9cf6_v1,
  title = {Incremental Selective Pressure for Modeling Acquired Resistance},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/incremental-selective-pressure-for-modeling-acquired-resistance/rdr_12fb9cf6632e456ab8663e08b2bc742b/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-22},
}